Safety and efficacy of canakinumab in Japanese patients with phenotypes of cryopyrin-associated periodic syndrome as established in the first open-label, phase-3 pivotal study (24-week results).
Authors:
- Tomoyuki ImagawaTITomoyuki Imagawa
- Ryuta NishikomoriRNRyuta Nishikomori
- Hidetoshi TakadaHTHidetoshi Takada
- Saoko TakeshitaSTSaoko Takeshita
- Neha PatelNPNeha Patel
- Dennis KimDKDennis Kim
- Karine LheritierKLKarine Lheritier
- Toshio HeikeTHToshio Heike
- Toshiro HaraTHToshiro Hara
- Shumpei YokotaSYShumpei Yokota
- 1 February 2013
- journal article
- Vol. 31 (2) , 302-9